Brief: Canbridge Pharmaceuticals Says Grant Of Priority Review Status Of CAN103
30/09/2024 13:30
Sept 30 (Reuters) - Canbridge Pharmaceuticals Inc
1228.HK :
* GRANT OF PRIORITY REVIEW STATUS OF CAN103 FOR TREATMENT OF
GAUCHER DISEASE
* PRIORITY REVIEW STATUS GRANTED BY CENTER FOR DRUG
EVALUATION OF
NMPA OF CHINA
Further company coverage: 1228.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CANbridge Pharmaceuticals
See all newsChina's CANbridge Pharmaceuticals H1 revenue rises on Hunterase and Livmarli strength
Brief: CANbridge Pharmaceuticals Posts HY Loss of RMB37.1 MLN
Brief: Canbridge Pharmaceuticals Says Livmarli Obtains NHIA Reimbursement Approval In Taiwan For ALGS And PFIC
Brief: Canbridge Pharmaceuticals Initiates Registration And Launch Preparations For Gaurunning In North African Market
CANbridge Pharmaceuticals jumps as WuXi Biologics buys shares